Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics' register GISEA
| Autor: | I. Farina, Giovanni Lapadula, Piercarlo Sarzi-Puttini, Fabiola Atzeni, Laura Bianchino, Alessandro Giollo, G. F. Ferraccioli, Ennio Giulio Favalli, Antonio Carletto, L. La Grasta, Elisa Gremese, Chiara Bazzani, Mauro Galeazzi, Roberto Gorla, Marcello Govoni, Luigi Sinigaglia, Rosario Foti, Florenzo Iannone |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Male Biologics Italy Real-world Registry Rheumatoid arthritis Tocilizumab Rheumatology Settore MED/16 - REUMATOLOGIA Arthritis Rheumatoid chemistry.chemical_compound 0302 clinical medicine Registries medicine.diagnostic_test Remission Induction General Medicine Middle Aged Safety profile Treatment Outcome Erythrocyte sedimentation rate Antirheumatic Agents Female Early arthritis medicine.drug musculoskeletal diseases Adult medicine.medical_specialty Antibodies Monoclonal Humanized NO Abatacept 03 medical and health sciences Internal medicine medicine Humans Adverse effect 030203 arthritis & rheumatology Biological Products business.industry Tumor Necrosis Factor-alpha medicine.disease 030104 developmental biology chemistry Immunology business |
| Zdroj: | Clinical rheumatology. 37(2) |
| ISSN: | 1434-9949 |
| Popis: | To assess the long-term effectiveness and safety of tocilizumab, abatacept, and tumor necrosis factor-α inhibitors (TNFi), in the Italian real-world setting of rheumatoid arthritis (RA). The records of adult RA patients from the Italian biologics’ registry Gruppo Italiano Studio Early Arthritis (GISEA) were analyzed. Demographic and clinical data were obtained at entry. The disease remission rate (28-joint disease activity score calculated using the erythrocyte sedimentation rate [DAS28-ESR] ≤ 2.6) and frequency of adverse events (AEs) were evaluated at 2 years. From 1999 to 2014, 7539 patients were treated with biologics (61.3% in first- and 22.6% in second-line), 68% of cases received TNFi, 9.1% tocilizumab, and 8.6% abatacept. Treatment groups showed a similar DAS28 at entry. As first-line, tocilizumab induced a significantly higher remission rate than abatacept or TNFi at 6 (51 vs 23.3 and 26.2%, respectively; p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink